The Global Idiopathic Pulmonary Fibrosis Market generated US$ 2,073.9 million in 2021 and is estimated to reach US$ 4,298.8 million by 2030, growing at a compound annual growth rate (CAGR) of 9.4%. According to data provided in a study by the National Organization for Rare Disorder (NORD), in the general population, estimates have ranged from 2-29 persons per 100,000. This heterogeneity could be due in part to the lack of a standardized definition when trying to diagnose the illness. Furthermore, many cases of Idiopathic pulmonary fibrosis go untreated or are misdiagnosed, making determining the true prevalence in the general population challenging. Approximately 5-10% of idiopathic pulmonary fibrosis cases are caused by a family member. Idiopathic pulmonary fibrosis primarily affects people in their fifties and sixties. Males are more likely to be impacted than females. The anticipated idiopathic pulmonary fibrosis market growth reflects the industry's recovery from Covid -19 and future growth trends. The report presents analysis detailed across 14 elucidated chapters totaling 187 pages, with 35 extensive data tables and 44 figures.

Idiopathic pulmonary fibrosis (IPF) is a kind of chronic lung disease in which the lungs scar and fibrosis occurs, resulting in persistent pulmonary function loss. The expanding generic population has a significant impact on the global idiopathic pulmonary fibrosis market. According to studies, the incidence of idiopathic pulmonary fibrosis in the young population is 5-6 instances per 100,000 individuals per year, compared to 11 cases per 100,000 persons over the age of 60. The report on the global market for idiopathic pulmonary fibrosis provides a thorough analysis of market opportunities, market dynamics, and the competitive environment of the Idiopathic pulmonary fibrosis industry. The global idiopathic pulmonary fibrosis market is analyzed from 2017 to 2030, with historic data from 2017 to 2019, the base year of 2020, and anticipated figures from 2022 to 2030. 

Idiopathic pulmonary fibrosis is a chronic disorder. Breathlessness is one of the most common Idiopathic pulmonary fibrosis symptoms, and it can make daily activities like showering, climbing stairs, getting dressed, and eating difficult. Breathlessness may prevent all activity when scarring in the lungs worsens. A chronic cough that lasts longer than 8 weeks affects about 85% of persons with Idiopathic pulmonary fibrosis. Although this is usually a dry cough, some persons may cough up mucus or phlegm.

Many lung disorders can cause dyspnea and cough, and some of these other diseases can have identical symptoms and X-ray results, making idiopathic pulmonary fibrosis difficult to identify. Physical examination of the lungs and other bodily parts such as the heart, joints, fingernails, skin, and muscles. Although no single test can identify Idiopathic pulmonary fibrosis, your doctor may suggest a variety of procedures, such as a pulmonary function test (PFT), a chest x-ray, blood tests, computed tomography (CT scan), bronchoscopy, and others.

Report Scope

The report provides a thorough analysis of market opportunities in the worldwide Idiopathic pulmonary fibrosis Market. The 7MM region consisting of the following countries have been extensively analyzed – U.S., UK, France, Germany, Spain, Italy, and Japan – for growth opportunities in the Idiopathic pulmonary fibrosis market. The report identifies the U.S. as the largest market with a US$ 1,171.8 Million market size in 2020 with the highest CAGR of 9.9%. The global prevalence of idiopathic pulmonary fibrosis is estimated to be 13 to 20 per 100,000 people. In the United States, about 100,000 people are affected, with 30,000 to 40,000 new cases identified each year. The random form of pulmonary fibrosis is less common than familial pulmonary fibrosis. One of the primary causes of Idiopathic pulmonary fibrosis is smoking. According to data provided by the Centers for Disease Control and Prevention (CDC), in 2019, over 14 out of every 100 adults in the United States aged 18 and up (14.0%) smoked cigarettes. This means that in the United States, approximately 34.1 million adults smoke cigarettes. A smoking-related ailment affects more than 16 million Americans.

The idiopathic pulmonary fibrosis market report includes market analysis on basis of therapies being used to treat or decrease the progression of Idiopathic pulmonary fibrosis disease. Globally, it has been observed that Esbriet (Pirfenidone), a prescription medicine originally developed by InterMune Inc., which later merged with Roche, dominated the market in 2020. Esbriet is an oral drug that has been licensed for the treatment of idiopathic pulmonary fibrosis in over 60 countries across the world. In October of 2014, the Food and Drug Administration (FDA) approved Esbriet for use in persons with Idiopathic pulmonary fibrosis. InterMune created Esbriet for usage in the United States, Europe, and other nations. In 2011, the European Union (EU) granted commercial permission for the treatment of people with mild to moderate Idiopathic pulmonary fibrosis. Another prescription medicine, OFEV was developed by Boehringer Ingelheim Pharma GmbH and Co. Kg whose active ingredient nintedanib is a tyrosine kinase inhibitor (TKI) that inhibits the growth factor receptors involved in the progress of pulmonary fibrosis. Both of these medications help individuals with Idiopathic pulmonary fibrosis live longer. Across all medication classifications, MAPK Inhibitors (Esbriet) has the biggest market share. However, due to the FDA's priority review, Tyrosine Kinase Inhibitors (OFEV) is predicted to increase in the idiopathic pulmonary fibrosis market over the forecast period.

Report Glimpse

The market has observed tremendous growth due to factors such as the world's increasingly aging population and the rise in smokers' population are expected to drive market growth higher. New idiopathic pulmonary fibrosis cases are often detected and progressed in the geriatric adult, but the disease's prevalence is typically low in the 18 to 60-year-old age group. Idiopathic pulmonary fibrosis is connected to smoking, which is a substantial risk factor. Furthermore, smoking tobacco has been associated with an increased risk of mortality in IPF patients. More than 16 million Americans are impacted by diseases connected to or induced by smoking, according to the Centers for Disease Control and Prevention (CDC). Thus, a growing number of smokers will foster the growth of the Idiopathic pulmonary fibrosis market over the forecast period.

Competition Landscape

The competition landscape section of the Idiopathic pulmonary fibrosis market report covers descriptive profiles of 12 prominent players and the list can be customized as per the reader’s research requirements. Details covered for these players include – Business description, company financials, and claims, key details, strategy outlook, list of products, and recent developments. The players profiled in the report include the following – Genentech, Inc., Boehringer Ingelheim Pharma GmbH, and Co. Kg, MediciNova, FibroGen, Inc., Kadmon Corporation, LLC, Promedior, Genkyotex, CelgeneCorporation, ProMetic LifeSciences, Biogen, Inc., Merck and Co. and Novartis. 

Segmentation Overview

By Therapy 

• Esbriet (Pirfenidone)
• Ofev (Nintedanib)
• Tipelukast
• Pamrevlumab
• KD025
• PRM 151
• GKT831
• Others

By Country

• The U.S.
• The UK
• France
• Germany
• Spain
• Italy
• Japan